Instrument Inactif

Autres langues InMed Pharmaceuticals Inc Canadian Securities Exchange

Actions

IN

CA4576371062

Recherche biotechnologique et médicale

Autres langues

07/07	InMed Pharmaceuticals Amends Deal With Mentari Therapeutics
07/07	InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
04/06	InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
19/05	InMed Pharmaceuticals Inc. announced that it expects to receive $290 million in funding from a group of investors
19/05	INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
19/05	InMed Pharmaceuticals InMed shareholders are expected to own approximately 1.51% of combined company
19/05	InMed Pharmaceuticals Amends Preferred Investment Options
07/05	InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
06/05	InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026
30/04	Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
27/04	InMed Pharmaceuticals Amends Preferred Investment Options
27/03	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
23/03	InMed Pharmaceuticals Announces Positive Data From Human Brain Organoid Neuroinflammation Models Supporting The INM-901 Alzheimer'S Disease Program
23/03	InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
09/03	InMed Pharmaceuticals Inc Provides Update on Pharmaceutical Development Programs
09/03	InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
06/03	InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
06/03	InMed Pharmaceuticals Inc confirms and approves decision to wind down Baymedica's commercial operations - SEC filing
11/02	InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
11/02	InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025
18/12	InMed Announces Results of 2025 Annual General and Special Meeting
15/12	Dated alerts on InMed Pharmaceuticals withdrawn
12/12	InMed Provides Update on BayMedica Commercial Business
18/11	InMed Pharmaceuticals Inc. Announces Successful Completion of Pharmacokinetic Studies in Large Animal Models for Its Alzheimer's Disease Candidate INM-901
18/11	InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901